Ng Alison, Keech Adam, Jones Lyndon
Centre for Ocular Research & Education (CORE), School of Optometry & Vision Science, University of Waterloo, Waterloo, ON, Canada.
Clin Ophthalmol. 2018 Apr 10;12:695-700. doi: 10.2147/OPTH.S150587. eCollection 2018.
To evaluate tear osmolarity after using a hydroxypropyl-guar (HP-guar)-based lubricating eye drop four times daily (QID) for 3 weeks.
Thirty-one participants with dry eye disease (Ocular Surface Disease Index [OSDI] score ≥20 and tear osmolarity ≥300 mOsm/L in at least one eye) were enrolled in this prospective, dispensing, non-randomized study involving a baseline visit and 3-week follow-up. Tear osmolarity, non-invasive tear break up time (NITBUT), conjunctival hyperemia, corneal and conjunctival staining were determined at baseline. Participants were instructed to instill one drop of a HP-guar-based drop QID in each eye for 3 weeks. At the follow-up visit, the symptoms and ocular surface parameters were reassessed. At this visit, one HP-guar drop was instilled into each eye and osmolarity was measured after 15 minutes, to examine short-term changes in osmolarity.
Twenty-eight participants completed the study (5M, 23F; median age 54 yrs, range 25-83 yrs). At baseline, mean OSDI score was 44.9±15.2 and mean osmolarities were 314.63±11.9/306.6±10.1 mOsm/L (worst eye [WE]/better eye [BE]). After 3 weeks, mean osmolarity reduced to 307.7±15.7/303.9±11.3 mOsm/L (WE/BE; <0.05 and =0.228, respectively) and mean OSDI scores reduced to 28.3±17.0 (<0.01). A significant reduction in osmolarity was observed 15 minutes after instilling the lubricating drop (<0.05 WE, =0.09 BE). Significant improvements in central corneal staining (<0.05 OU) and NITBUT (<0.05 WE only) were observed. Reductions in conjunctival staining and hyperemia were observed, but were not significant (>0.05).
A significant reduction in tear osmolarity and improvements in dry eye symptoms, corneal staining, and NITBUT were observed after 3 weeks of QID use of a HP-guar-based lubricant drop. A decrease in osmolarity was also demonstrated 15 minutes after drop instillation.
评估每天四次（QID）使用基于羟丙基瓜尔胶（HP-瓜尔胶）的润滑眼药水，持续3周后的泪液渗透压。
31名患有干眼病的参与者（眼表疾病指数[OSDI]评分≥20且至少一只眼睛的泪液渗透压≥300 mOsm/L）被纳入这项前瞻性、配药、非随机研究，该研究包括一次基线访视和3周的随访。在基线时测定泪液渗透压、非侵入性泪膜破裂时间（NITBUT）、结膜充血、角膜和结膜染色情况。参与者被指示每只眼睛每天四次滴入一滴基于HP-瓜尔胶的眼药水，持续3周。在随访时，重新评估症状和眼表参数。在这次访视中，每只眼睛滴入一滴HP-瓜尔胶眼药水，并在15分钟后测量渗透压，以检查渗透压的短期变化。
28名参与者完成了研究（5名男性，23名女性；年龄中位数54岁，范围25 - 83岁）。在基线时，平均OSDI评分为44.9±15.2，平均渗透压为314.63±11.9/306.6±10.1 mOsm/L（最差眼[WE]/较好眼[BE]）。3周后，平均渗透压降至307.7±15.7/303.9±11.3 mOsm/L（WE/BE；分别<0.05和=0.228），平均OSDI评分降至28.3±17.0（<0.01）。滴入润滑眼药水15分钟后观察到渗透压显著降低（最差眼<0.05，较好眼=0.09）。观察到中央角膜染色（双眼<0.05）和NITBUT（仅最差眼<0.05）有显著改善。结膜染色和充血有所减轻，但不显著（>0.05）。
每天四次使用基于HP-瓜尔胶的润滑眼药水3周后，观察到泪液渗透压显著降低，干眼症状、角膜染色和NITBUT有所改善。滴入眼药水15分钟后也显示渗透压降低。
